Pamidronat Dinatrium Pfizer (Pamidronate Disodium)

Pamidronate Disodium, the active ingredient in Pamidronat Dinatrium Pfizer, is a bisphosphonate presented as a intravenous solution for intravenous use. It is used to treat conditions involving excessive bone resorption, particularly in patients with malignancy‑related bone disease and certain metabolic bone disorders. GNH USA supplies Pamidronat Dinatrium Pfizer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Pamidronat Dinatrium Pfizer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Pamidronate Disodium is indicated for several bone‑related conditions where inhibition of osteoclast activity is required.

- Hypercalcaemia of malignancy: reduces serum calcium levels in cancer patients. - Bone metastases: helps prevent skeletal‑related events such as fractures. - Paget’s disease of bone: normalises abnormal bone remodeling. - Osteolysis associated with multiple myeloma: limits bone loss. - Hyperparathyroidism (post‑surgical): assists in controlling postoperative calcium spikes. - Osteoporosis (investigational): evaluated in clinical trials for bone density improvement.

Adverse reactions to pamidronate are reported across a spectrum of frequency and severity.

Common Side Effects: - Fluoro‑like symptoms: fever, myalgia, arthralgia, and chills. - Nausea or vomiting. - Transient elevation of serum creatinine. - Headache. - Injection‑site discomfort or phlebitis. - Fatigue.

Serious or Rare Side Effects: - Acute renal insufficiency or failure. - Severe hypocalcaemia. - Atypical femoral fractures. - Osteonecrosis of the jaw. - Anaphylactic or severe hypersensitivity reactions. - Cardiac arrhythmias (rare).

When using pamidronate, clinicians should assess patient‑specific risk factors and monitor relevant clinical parameters.

- Renal function: evaluate baseline creatinine and adjust if impairment exists. - Calcium levels: correct hypocalcaemia before infusion. - Concomitant nephrotoxic drugs: avoid or use with caution. - Hydration status: ensure adequate pre‑ and post‑infusion fluids. - Pregnancy and lactation: contraindicated unless benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pamidramate may interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid): - Aminoglycosides: increased risk of nephrotoxicity. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may worsen renal impairment. - Loop diuretics: potentiate renal toxicity when combined.

Moderate Interactions (Monitor Closely): - Calcium‑containing supplements or antacids: can reduce pamidronate binding to bone. - Vitamin D analogues: may alter calcium homeostasis. - Corticosteroids: additive effect on bone turnover. - Anticoagulants (e.g., warfarin): may require INR monitoring. - Oral bisphosphonates: concurrent use can increase cumulative bone‑targeting effects.